NDAORALFOR SOLUTION
Approved
Aug 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
POKONZA (potassium chloride) by Ascentage Pharma is (k) is the principal intracellular cation of most body tissues. Approved for bowel preparation. First approved in 2015.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POKONZA (potassium chloride) is an oral solution for bowel preparation that replaces potassium, the principal intracellular cation essential for nerve impulse transmission, muscle contraction, and renal function. It restores normal potassium levels in patients with depletion caused by diuretics, diarrhea, or other gastrointestinal losses. The drug works by active ion transport to maintain the critical potassium gradient across cell membranes.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30); limited financial data suggests niche positioning within bowel prep market with stable but not expanding team requirements.
Mechanism of Action
(K) is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the…
Indications (1)
Worked on POKONZA at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.